CSPC Pharmaceutical (HKG:1093) said China's National Medical Products Administration accepted the new drug application for its independently developed Sirolimus for Injection, according to a Monday filing with the Hong Kong bourse.
The application seeks approval for the treatment of unresectable locally advanced or metastatic malignant perivascular epithelioid cell tumor (PEComa).